Order Article Reprints

Manore S, Zhuang C, Najjar MK, Wong GL, Bindal S, Watabe K, Lin J, Lo H-W. Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers. Cells. 2024; 13(24):2087. https://doi.org/10.3390/cells13242087

Manore, Sara, Chuling Zhuang, Mariana K. Najjar, Grace L. Wong, Shivani Bindal, Kounosuke Watabe, Jiayuh Lin, and Hui-Wen Lo. 2024. "Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers" Cells 13, no. 24: 2087. https://doi.org/10.3390/cells13242087

Manore, S., Zhuang, C., Najjar, M. K., Wong, G. L., Bindal, S., Watabe, K., Lin, J., & Lo, H.-W. (2024). Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers. Cells, 13(24), 2087. https://doi.org/10.3390/cells13242087